CADL vs REPL
CADL: A clinical-stage biotechnology firm pioneering viral immunotherapies to spark systemic immune responses against cancer. REPL: Replimune is an oncolytic immunotherapy company developing viral-based therapies that turn "cold" tumors "hot" to induce a potent, systemic immune response against cancer.
Side-by-side fundamentals
| Metric | CADL | REPL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $9.66 | $13.04 | |
| Market cap | $739M | $1.2B | |
| Net margin FY2022, SEC XBRL | -15035.2% | n/a | |
| Operating margin FY2022, SEC XBRL | -27777.6% | n/a | |
| ROE | -73.5% | -188.9% | CADL higher |
| ROA | -30.5% | -94.4% | CADL higher |
| Debt / equity as of 2026-09-03 | 0.34 | 0.65 | CADL lower |
| Revenue CAGR (3y) SEC XBRL | +0.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.77 | 0.58 | |
| 1-year return as of 2026-10-08 close | +53.3% | +185.3% | REPL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.